MENU

ABBV ABBVIE Forecast, Technical & Fundamental Analysis

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more

A.I.Advisor
Nov 07, 2026

AbbVie (ABBV) Stock Forecast: New Indications and Pipeline Readouts Set the Next Phase of Growth

Key Takeaways

  • Upcoming catalysts: U.S. Food and Drug Administration (FDA) decisions on Rinvoq for vitiligo and alopecia areata, a subcutaneous Skyrizi induction approval for Crohn's disease, and Phase 3 data in hidradenitis suppurativa (HS) and lupus could expand AbbVie's immunology franchise in 2026 and 2027.
  • Strategic positioning: Skyrizi and Rinvoq are on track to exceed $31 billion in combined 2026 sales, more than offsetting the ongoing erosion of legacy blockbuster Humira and anchoring management's high-single-digit compound annual revenue growth target through 2029.
  • Industry tailwinds and headwinds: Robust demand in immunology, neuroscience, and oncology supports growth, while new oral psoriasis competition from Johnson & Johnson's Icotyde and low-single-digit pricing pressure present offsets.
  • Macro sensitivity: Inflation Reduction Act (IRA) Medicare drug-price negotiations and payer rebates are a structural pricing headwind, with management flagging Vraylar pricing changes as a 2027 impact.
  • Analyst sentiment: Wall Street consensus is broadly bullish, with an average 12-month price target near $310 and a range spanning roughly $237 to $350, according to recent polling of nearly 30 analysts.
  • Key risks: Slower-than-expected new-indication uptake, intensified biosimilar and branded competition, and a continued drag in the aesthetics segment could temper the growth trajectory.
  • For deeper detail on this ticker's Major News, Today's Price Move, Price Targets, and Earnings, explore the dedicated ABBV pages for a fuller picture of market activity and consensus data.
  • For automated, AI-driven trade ideas across a range of assets, explore Trending AI Robots.

Strategic Positioning and Competitive Outlook

AbbVie has largely completed the difficult transition away from Humira, which lost U.S. exclusivity in 2023 and continues to decline in the face of biosimilar competition. The company's medium-term positioning now rests on two immunology franchises with durable momentum. Skyrizi captured about half of new patient starts in inflammatory bowel disease (IBD), while Rinvoq is expanding into dermatology and rheumatology indications. Together, these products accounted for more than 47% of total revenue by mid-2026, and management expects combined sales above $31 billion this year.

The company is also laying the groundwork for its next immunology cycle. The roughly $10.9 billion acquisition of Apogee Therapeutics added zumilokibart, a late-stage anti-IL-13 (interleukin-13) antibody targeting atopic dermatitis, positioning AbbVie to compete with the category-leading Dupixent. Beyond immunology, a growing neuroscience portfolio led by Vraylar, Ubrelvy, Qulipta, and the newly approved Parkinson's therapy Juvmo provides diversification, with management guiding the Parkinson's franchise toward more than $5 billion in peak sales.

Major Catalysts Ahead

Several regulatory and clinical milestones could reshape investor expectations over the next several quarters. The FDA is reviewing Rinvoq for vitiligo and alopecia areata, with a U.S. decision on vitiligo expected later in 2026 and on alopecia areata in early 2027; management estimates the two dermatology indications could add nearly $2 billion in combined peak sales. A subcutaneous induction approval for Skyrizi in Crohn's disease is also anticipated, improving convenience and potentially accelerating patient-share gains in 2027.

In the pipeline, Phase 3 readouts for Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus, along with lutikizumab data in HS, represent the next wave of label expansion. In oncology, positive Phase 3 results for etentamig in multiple myeloma have supported a U.S. regulatory submission, with a decision expected in 2027. Analyst ratings have trended more optimistic, with firms such as Morgan Stanley, Wells Fargo, and Leerink Partners raising price targets in recent months, reflecting growing confidence in the growth trajectory.

Industry and Macroeconomic Forces

AbbVie's trajectory is shaped by a mix of secular demand and policy-driven pricing pressure. Immunology markets for conditions such as atopic dermatitis and asthma are growing 15% to 20% annually, providing a favorable demand backdrop. At the same time, the Inflation Reduction Act's Medicare drug-price negotiation framework introduces a structural pricing headwind, with management highlighting Vraylar pricing changes as a 2027 impact and an ongoing dispute over Botox's eligibility for negotiation.

Interest rates and inflation affect AbbVie primarily through capital-allocation and valuation channels rather than direct demand, given the relatively inelastic nature of many specialty pharmaceuticals. However, the aesthetics segment, which has seen softer dermal filler demand, remains more exposed to discretionary consumer spending cycles. Geopolitical and supply-chain considerations are modest for a U.S.-centric specialty portfolio, though foreign-exchange movements can influence reported revenue.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The platform also offers searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking AbbVie's evolving outlook, tools like this can add a data-driven layer to traditional fundamental analysis.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, AbbVie's guidance for approximately $67.8 billion in full-year revenue and adjusted earnings of $13.95 to $13.99 per share reflects continued double-digit growth from Skyrizi and Rinvoq. Management has pointed to high-single-digit compound annual revenue growth through 2029, supported by a pipeline with no major loss-of-exclusivity events expected to materially disrupt the business this decade.

Longer-term, investors will watch whether combination immunology regimens built around Skyrizi with ABBV-382 and ABBV-701 can deliver best-in-class, durable remission in IBD, and whether the oncology pipeline—including etentamig and Epkinly—can scale into meaningful revenue contributors. Capital allocation priorities remain balanced, with a 5.2% dividend increase to $1.82 per share and a focus on bolt-on acquisitions in immunology, neuroscience, oncology, and obesity. Consensus analyst expectations, with an average price target near $310, suggest the market broadly anticipates continued execution, though regulatory outcomes and competitive dynamics remain key variables to monitor.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

ABBV is expected to report earnings to rise 2.62% to $3.92 per share on February 03

ABBVIE ABBV Stock Earnings Reports
Q4'26
Est.
$3.92
Q3'26
Beat
by $0.08
Q2'26
Missed
by $0.06
Q1'26
Beat
by $0.06
Q4'25
Beat
by $0.06
The last earnings report on October 30 showed earnings per share of $3.82, beating the estimate of $3.74. With 8.77M shares outstanding, the current market capitalization sits at 514.78B.
A.I.Advisor
published Dividends

ABBV paid dividends on November 16, 2026

ABBVIE ABBV Stock Dividends
А quarterly dividend of $1.73 per share was paid with a record date of November 16, 2026, and an ex-dividend date of October 15, 2026. Read more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MTEX2.560.11
+4.49%
Mannatech
SBR60.83-0.66
-1.07%
Sabine Royalty Trust
FER57.34-1.69
-2.86%
Ferrovial NV
BNC3.06-0.34
-10.00%
BNB Standard Corporation
MXL41.45-6.68
-13.88%
MaxLinear

ABBV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
+0.94%
NVS - ABBV
52%
Loosely correlated
-0.50%
BMY - ABBV
51%
Loosely correlated
+0.79%
JNJ - ABBV
51%
Loosely correlated
+1.25%
AMGN - ABBV
49%
Loosely correlated
-0.15%
GILD - ABBV
47%
Loosely correlated
-0.06%
More
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
57000
Web
https://www.abbvie.com
AbbVie (ABBV) Stock Forecast: New Indications and Pipeline Readouts Set the Next Phase of Growth